Zelgen Reports ZG006 Pivotal Interim Endpoint in SCLC

Company Zelgen (Suzhou Zelgen Biopharmaceuticals) Event Type Pivotal interim analysis (company filing) Modality DLL3/DLL3/CD3 trispecific T-cell engager Asset Alveltamig (ZG006) Target DLL3; CD3 Disease Area Third-line or later small-cell lung cancer Summary Zelgen disclosed that an independent monitoring committee found its randomized Chinese pivotal interim…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *